康华生物(300841) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥319,293,940.97, a decrease of 10.21% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥99,347,384.56, down 17.71% year-on-year[3]. - The basic earnings per share for Q3 2024 was ¥0.7602, reflecting a decline of 15.79% compared to the previous year[3]. - Total operating revenue for Q3 2024 reached ¥1,060,378,720.25, an increase of 7.07% compared to ¥990,055,021.87 in the same period last year[16]. - Operating profit for Q3 2024 was ¥462,651,015.19, up 13.24% from ¥408,526,287.21 in Q3 2023[17]. - Net profit for Q3 2024 amounted to ¥405,902,226.46, representing a growth of 10.03% compared to ¥368,938,090.47 in Q3 2023[17]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥3,950,766,940.66, a decrease of 6.14% from the end of the previous year[3]. - Total assets as of the end of Q3 2024 were ¥3,950,766,940.66, down from ¥4,209,268,312.24 at the end of Q3 2023[15]. - Total liabilities decreased to ¥496,007,941.01 from ¥695,216,564.86 year-over-year[15]. - The company's equity attributable to shareholders was ¥3,454,758,999.65, slightly down from ¥3,514,051,747.38 in the previous year[15]. Cash Flow - The company reported a net cash flow from operating activities of ¥252,922,835.47, down 4.56% year-on-year[8]. - Cash inflow from operating activities totaled 1,128,507,441.97 yuan, up from 1,009,078,054.00 yuan, indicating an increase of about 11.8%[18]. - Net cash flow from operating activities decreased to 252,922,835.47 yuan from 265,007,516.70 yuan, a decline of approximately 4.0%[18]. - The net cash flow from investing activities was -¥94,553,184.38, an improvement of 15.57% compared to the previous year[8]. - Cash outflow from investing activities was 196,580,140.84 yuan, compared to 111,997,981.88 yuan in the previous period, reflecting an increase of about 75.5%[19]. - Net cash flow from investing activities was -94,553,184.38 yuan, an improvement from -111,993,981.88 yuan year-over-year[19]. - The company's cash flow from financing activities was -¥436,986,960.40, a significant increase of 710.00% year-on-year due to cash dividends and share repurchases[8]. - Cash inflow from financing activities was 206,344,705.68 yuan, up from 131,754,880.79 yuan, marking an increase of approximately 56.5%[19]. - Net cash flow from financing activities decreased to -436,986,960.40 yuan from -53,949,194.47 yuan, indicating a significant decline[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,919, with the largest shareholder, Aokang Group Co., Ltd., holding 12.11% of shares, equating to 16,305,468 shares[9]. - Wang Zhentao, a significant shareholder, holds 10.40% of shares, totaling 14,004,687 shares, with 10,503,515 shares under lock-up conditions[9]. - The total number of preferred shareholders is not applicable, indicating no preferred shares are currently issued[11]. - The company has a total of 16,274,126 restricted shares, with 3,854,987 shares released during the period[12]. - Wang Zhentao's restricted shares decreased to 10,503,515 after 3,450,000 shares were released[11]. Research and Development - Research and development expenses for the year-to-date period were ¥92,407,491.66, a decrease of 50.30% compared to the same period last year[7]. - Research and development expenses for Q3 2024 were ¥92,407,491.66, a decrease of 50.32% from ¥185,927,273.77 in the same quarter last year[16]. - The company experienced a 44.62% increase in income tax expenses, totaling ¥56,534,637.67, due to increased profit and reduced R&D expense deductions[7]. Market Strategy - The company is exploring market expansion strategies, although specific details were not disclosed in the report[10].